表位特异性DerG-PG70 LEAPS疫苗调节T细胞反应并在两种相关小鼠类风湿关节炎模型中抑制关节炎进展
研究在蛋白聚糖诱导性关节炎(PGIA)和G1结构域诱导性关节炎(GIA)两种Th1细胞驱动的小鼠类风湿关节炎模型中,于症状出现后给予DerG-PG70或J-PG70 LEAPS疫苗。DerG-PG70显著降低关节炎视觉与组织病理学评分、抑制疾病进展,J-PG70无效;DerG-PG70使脾CD4+细胞中Th1、Th17减少而Th2、调节性T细胞增多,细胞因子由促炎向抗炎/调节性偏移,且DerG-PG70肽四聚体优先结合GIA脾细胞CD4+ T细胞。
要点
- DerG-PG70疫苗在PGIA和GIA两种小鼠模型中于症状出现后给药,显著降低关节炎视觉与组织病理学评分并抑制疾病进展。
- J-PG70疫苗在相同模型中无效。
- DerG-PG70使脾CD4+细胞Th1、Th17减少、Th2与Treg增多,细胞因子由促炎向抗炎/调节性偏移。
核心结论
- DerG-PG70疫苗(现命名为CEL-4000)通过作用于CD4+细胞,在PGIA和GIA两种类风湿关节炎模型中产生抗原特异性下调致病性T细胞反应的治疗效果。
- 未来研究需确定LEAPS疫苗接种能否在类风湿关节炎患者中提供疾病抑制。
研究设计与样本
- 在两种Th1细胞驱动的小鼠类风湿关节炎模型——软骨蛋白聚糖诱导性关节炎(PGIA)和蛋白聚糖G1结构域诱导性关节炎(GIA)中测试LEAPS疫苗的治疗效果。
- 将免疫优势蛋白聚糖肽PG70连接至DerG或J免疫细胞结合肽,在PGIA或GIA症状出现后给予小鼠DerG-PG70和J-PG70 LEAPS疫苗。
主要发现
- 以关节炎视觉评分和组织病理学评分的显著下降为指标,DerG-PG70疫苗在PGIA和GIA中均抑制疾病进展,而J-PG70疫苗无效。
- DerG-PG70处理小鼠的脾CD4+细胞中Th1和Th17群体减少,Th2和调节性T(Treg)细胞富集。
- DerG-PG70处理小鼠的体外脾细胞分泌细胞因子和血清细胞因子显示由促炎向抗炎/调节性特征偏移。
- DerG-PG70肽四聚体优先结合GIA脾细胞的CD4+ T细胞。
局限性
- 原文指出未来研究需确定LEAPS疫苗接种能否在类风湿关节炎患者中提供疾病抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rheumatoid arthritis (RA) is an autoimmune joint disease maintained by aberrant immune responses involving CD4+ T helper (Th)1 and Th17 cells. In this study, we tested the therapeutic efficacy of Ligand Epitope Antigen Presentation System (LEAPS™) vaccines in two Th1 cell-driven mouse models of RA, cartilage proteoglycan (PG)-induced arthritis (PGIA) and PG G1-domain-induced arthritis (GIA). The immunodominant PG peptide PG70 was attached to a DerG or J immune cell binding peptide, and the DerG-PG70 and J-PG70 LEAPS vaccines were administered to the mice after the onset of PGIA or GIA symptoms. As indicated by significant decreases in visual and histopathological scores of arthritis, the DerG-PG70 vaccine inhibited disease progression in both PGIA and GIA, while the J-PG70 vaccine was ineffective. Splenic CD4+ cells from DerG-PG70-treated mice were diminished in Th1 and Th17 populations but enriched in Th2 and regulatory T (Treg) cells. In vitro spleen cell-secreted and serum cytokines from DerG-PG70-treated mice demonstrated a shift from a pro-inflammatory to an anti-inflammatory/regulatory profile. DerG-PG70 peptide tetramers preferentially bound to CD4+ T-cells of GIA spleen cells. We conclude that the DerG-PG70 vaccine (now designated CEL-4000) exerts its therapeutic effect by interacting with CD4+ cells, which results in an antigen-specific down-modulation of pathogenic T-cell responses in both the PGIA and GIA models of RA. Future studies will need to determine the potential of LEAPS vaccination to provide disease suppression in patients with RA.
引用
- Mikecz K, Glant TT, Markovics A, et al. An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis. Vaccine. 2017. PMID: 28583308. doi:10.1016/j.vaccine.2017.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。